Global Erythropoietin Drugs Market Size study & Forecast, by Type (Biologics, Biosimilars), by Product (Erythropoietin, Darbepoetin-alfa), by Application (Cancer, Renal Disease, Neurology, Others), and Regional Analysis, 2023-2030

Global Erythropoietin Drugs Market Size study & Forecast, by Type (Biologics, Biosimilars), by Product (Erythropoietin, Darbepoetin-alfa), by Application (Cancer, Renal Disease, Neurology, Others), and Regional Analysis, 2023-2030

Global Erythropoietin Drugs Market is valued at approximately USD 6.87 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.5% during the forecast period 2023-2030. Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone that stimulates the production of red blood cells in the bone marrow, a process known as erythropoiesis. Initially developed to address anemic conditions arising from End-Stage Renal Disease (ESRD) and related treatments such as dialysis, EPO drugs have expanded their applications. Following successful Post-abbreviated New Drug Application (ANDA) approvals, EPO drugs have been increasingly sanctioned for managing chemotherapy-induced anemia. The market growth is driven by key factors such as the rising incidence of chronic diseases and the rising number of CKD cases.

The growth can be attributed to the rising incidence of chronic diseases such as cancer, end-stage renal diseases, HIV, and neurological diseases. As per Statista, the prevalence of individuals experiencing at least two chronic diseases in Italy varied between 2010 and 2022, exhibiting an overall upward trend. In 2018, the peak was observed, with over 12.9 million people affected by at least two chronic diseases. By 2022, approximately 12.6 million Italians were grappling with at least two chronic diseases.. Furthermore, By the year 2050, it is anticipated that this number will surge to approximately 171 million. The prevalence of individuals with chronic conditions in the United States has been on a gradual rise since 1995. This data depicts the count of individuals with chronic medical conditions in the United States spanning from 1995 to 2020, along with projections for 2025 and 2050. However, the launch of alternative drugs and increased demand for EPO Side effects stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Erythropoietin Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the overall erythropoietin drugs market in terms of the revenue share of XX% in 2022. The regional market is anticipated to significantly benefit from local organizations that are actively engaged in advancing the development and use of erythropoietin drugs. Along with this, Asia Pacific is expected to witness fastest growth with CAGR XX% over the forecast period. The growth of the region is attributed to the presence of key players in the market and strategic initiatives undertaken by them to develop and commercialize new erythropoietin drug products to treat anemia patients.

Major market player included in this report are:
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
Intas Pharmaceuticals Ltd.
Novartis AG
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
LG Chem
Biocon
Sun Pharmaceutical Industries Ltd
Dr. Reddy’s Laboratories Ltd


Recent Developments in the Market:
 In November 2022, Dong-A ST forged a strategic partnership with Polifarma regarding the DA-3880 NESP biosimilar. This collaboration granted Polifarma the right to commercialize and advance the development of DA-3880 in the markets of Brazil, Mexico, and Turkey.

 In September 2021, Wanbang Biopharma obtained approval from the National Medical Products Administration (NMPA) for Yi Bao (Human Erythropoietin Injection). This approval signifies its intended use in addressing chemotherapy-related anemia in individuals with non-myeloid malignancies.


Global Erythropoietin Drugs Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Application, Type, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Erythropoietin
Darbepoetin-alfa


By Type:
Biologics
Biosimilars

By Application:
Cancer
Renal Diseases
Neurology
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
Intas Pharmaceuticals Ltd.
Novartis AG
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
LG Chem
Biocon
Sun Pharmaceutical Industries Ltd
Dr. Reddy’s Laboratories Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.